Primidon

Primidon
Klinički podaci
Prodajno ime	Apo-Primidone, Cyral, Desoxyphenobarbitone, Hexadiona
Drugs.com	Monografija
Način primene	Oralno
Farmakokinetički podaci
Poluvreme eliminacije	3-23 h
Identifikatori
CAS broj	125-33-7
ATC kod	D08AC04 (WHO), N03AA03
PubChem	CID 4909
DrugBank	DB00794
ChemSpider	4740
KEGG	C07371
ChEMBL	CHEMBL856
Hemijski podaci
Formula	C12H14N2O2
Molarna masa	218,252
	SMILES CCC1(C(=O)NCNC1=O)C1=CC=CC=C1; ;
	InChI InChI=1S/C12H14N2O2/c1-2-12(9-6-4-3-5-7-9)10(15)13-8-14-11(12)16/h3-7H,2,8H2,1H3,(H,13,15)(H,14,16) ; Key:DQMZLTXERSFNPB-UHFFFAOYSA-N ;
Fizički podaci
Tačka topljenja	2.815 °C (5.099 °F)

Primidon je organsko jedinjenje, koje sadrži 12 atoma ugljenika i ima molekulsku masu od 218,252 Da.^[1]^[2]^[3]^[4]^[5]^[6]^[7]

Osobine

Osobina	Vrednost
Broj akceptora vodonika	2
Broj donora vodonika	2
Broj rotacionih veza	2
Particioni koeficijent^[8] (ALogP)	0,9
Rastvorljivost^[9] (logS, log(mol/L))	-2,3
Polarna površina^[10] (PSA, Å²)	58,2

Reference

^ Murphy K, Delanty N (2000 Nov). . „Primary Generalized Epilepsies”. Curr Treat Options Neurol. 2 (6): 527—542. PMID 11096777. doi:10.1007/s11940-000-0031-0. Проверите вредност парамет(а)ра за датум: |date= (помоћ)
^ Kagitani-Shimono K, Imai K, Okamoto N, Ono J, Okada S: Unverricht-Lundborg disease with cystatin B gene abnormalities. Kagitani-Shimono, K.; Imai, K.; Okamoto, N.; Ono, J.; Okada, S. (2002 Jan). . „Unverricht-Lundborg disease with cystatin B gene abnormalities”. Pediatr Neurol. 26 (1): 55—60. PMID 11814737. doi:10.1016/s0887-8994(01)00336-8. Проверите вредност парамет(а)ра за датум: |date= (помоћ)
^ Brown GM, Stone GH, Rathbone MP: Primidone and rapid cycling affective disorders. Lancet. Brown, G. M.; Stone, G. H.; Rathbone, M. P. (1993 Oct 9). . „Primidone and rapid cycling affective disorders”. Lancet (London, England). 342 (8876): 925. PMID 8105181. doi:10.1016/0140-6736(93)91972-o. Проверите вредност парамет(а)ра за датум: |date= (помоћ)
^ Schaffer LC, Schaffer CB, Caretto J (1999 Jun). . „The use of primidone in the treatment of refractory bipolar disorder”. Ann Clin Psychiatry. 11 (2): 61—6. PMID 10440522. doi:10.1023/a:1022338330606. Проверите вредност парамет(а)ра за датум: |date= (помоћ)
^ Young MC, Hughes IA (1991 Jan). . „Loss of therapeutic control in congenital adrenal hyperplasia due to interaction between dexamethasone and primidone”. Acta Paediatr Scand. 80 (1): 120—4. PMID 2028784. doi:10.1111/j.1651-2227.1991.tb11744.x. Проверите вредност парамет(а)ра за датум: |date= (помоћ)
^ Knox, C.; Law, V.; Jewison, T.; Liu, P.; Ly, S.; Frolkis, A.; Pon, A.; Banco, K.; Mak, C.; Neveu, V.; Djoumbou, Y.; Eisner, R.; Guo, A. C.; Wishart, D. S. (2011). . „DrugBank 3.0: A comprehensive resource for 'Omics' research on drugs”. Nucleic Acids Research. 39 (Database issue): D1035—D1041. PMC 3013709 . PMID 21059682. doi:10.1093/nar/gkq1126.
^ Wishart, David S.; Knox, Craig; Guo, An Chi; Cheng, Dean; Shrivastava, Savita; Tzur, Dan; Gautam, Bijaya; Hassanali, Murtaza (2008). . „DrugBank: A knowledgebase for drugs, drug actions and drug targets”. Nucleic Acids Research. 36 (Database issue): D901—D906. PMC 2238889 . PMID 18048412. doi:10.1093/nar/gkm958.
^ Ghose, Arup K.; Viswanadhan, Vellarkad N.; Wendoloski, John J. (1998). . „Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragmental Methods: An Analysis of ALOGP and CLOGP Methods”. The Journal of Physical Chemistry A. 102 (21): 3762—3772. Bibcode:1998JPCA..102.3762G. doi:10.1021/jp980230o.
^ Tetko, Igor V.; Tanchuk, Vsevolod Yu.; Kasheva, Tamara N.; Villa, Alessandro E. P. (2001). . „Estimation of Aqueous Solubility of Chemical Compounds Using E-State Indices”. Journal of Chemical Information and Computer Sciences. 41 (6): 1488—1493. PMID 11749573. doi:10.1021/ci000392t.
^ Ertl, Peter; Rohde, Bernhard; Selzer, Paul (2000). . „Fast Calculation of Molecular Polar Surface Area as a Sum of Fragment-Based Contributions and Its Application to the Prediction of Drug Transport Properties”. Journal of Medicinal Chemistry. 43 (20): 3714—3717. PMID 11020286. doi:10.1021/jm000942e.

Literatura

Hardman JG, Limbird LE, Gilman AG (2001). Goodman & Gilman's The Pharmacological Basis of Therapeutics (10. изд.). New York: McGraw-Hill. ISBN 0071354697. doi:10.1036/0071422803.
Thomas L. Lemke; David A. Williams, ур. (2007). Foye's Principles of Medicinal Chemistry (6. изд.). Baltimore: Lippincott Willams & Wilkins. ISBN 0781768799.

Spoljašnje veze

Primidone

Molimo Vas, obratite pažnju na važno upozorenje
u vezi sa temama iz oblasti medicine (zdravlja).

[1] Murphy K, Delanty N (2000 Nov). . „Primary Generalized Epilepsies”. Curr Treat Options Neurol. 2 (6): 527—542. PMID 11096777. doi:10.1007/s11940-000-0031-0. Проверите вредност парамет(а)ра за датум: |date= (помоћ)

[2] Kagitani-Shimono K, Imai K, Okamoto N, Ono J, Okada S: Unverricht-Lundborg disease with cystatin B gene abnormalities. Kagitani-Shimono, K.; Imai, K.; Okamoto, N.; Ono, J.; Okada, S. (2002 Jan). . „Unverricht-Lundborg disease with cystatin B gene abnormalities”. Pediatr Neurol. 26 (1): 55—60. PMID 11814737. doi:10.1016/s0887-8994(01)00336-8. Проверите вредност парамет(а)ра за датум: |date= (помоћ)

[3] Brown GM, Stone GH, Rathbone MP: Primidone and rapid cycling affective disorders. Lancet. Brown, G. M.; Stone, G. H.; Rathbone, M. P. (1993 Oct 9). . „Primidone and rapid cycling affective disorders”. Lancet (London, England). 342 (8876): 925. PMID 8105181. doi:10.1016/0140-6736(93)91972-o. Проверите вредност парамет(а)ра за датум: |date= (помоћ)

[4] Schaffer LC, Schaffer CB, Caretto J (1999 Jun). . „The use of primidone in the treatment of refractory bipolar disorder”. Ann Clin Psychiatry. 11 (2): 61—6. PMID 10440522. doi:10.1023/a:1022338330606. Проверите вредност парамет(а)ра за датум: |date= (помоћ)

[5] Young MC, Hughes IA (1991 Jan). . „Loss of therapeutic control in congenital adrenal hyperplasia due to interaction between dexamethasone and primidone”. Acta Paediatr Scand. 80 (1): 120—4. PMID 2028784. doi:10.1111/j.1651-2227.1991.tb11744.x. Проверите вредност парамет(а)ра за датум: |date= (помоћ)

[6] Knox, C.; Law, V.; Jewison, T.; Liu, P.; Ly, S.; Frolkis, A.; Pon, A.; Banco, K.; Mak, C.; Neveu, V.; Djoumbou, Y.; Eisner, R.; Guo, A. C.; Wishart, D. S. (2011). . „DrugBank 3.0: A comprehensive resource for 'Omics' research on drugs”. Nucleic Acids Research. 39 (Database issue): D1035—D1041. PMC 3013709 . PMID 21059682. doi:10.1093/nar/gkq1126.

[7] Wishart, David S.; Knox, Craig; Guo, An Chi; Cheng, Dean; Shrivastava, Savita; Tzur, Dan; Gautam, Bijaya; Hassanali, Murtaza (2008). . „DrugBank: A knowledgebase for drugs, drug actions and drug targets”. Nucleic Acids Research. 36 (Database issue): D901—D906. PMC 2238889 . PMID 18048412. doi:10.1093/nar/gkm958.

[8] Ghose, Arup K.; Viswanadhan, Vellarkad N.; Wendoloski, John J. (1998). . „Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragmental Methods: An Analysis of ALOGP and CLOGP Methods”. The Journal of Physical Chemistry A. 102 (21): 3762—3772. Bibcode:1998JPCA..102.3762G. doi:10.1021/jp980230o.

[9] Tetko, Igor V.; Tanchuk, Vsevolod Yu.; Kasheva, Tamara N.; Villa, Alessandro E. P. (2001). . „Estimation of Aqueous Solubility of Chemical Compounds Using E-State Indices”. Journal of Chemical Information and Computer Sciences. 41 (6): 1488—1493. PMID 11749573. doi:10.1021/ci000392t.

[10] Ertl, Peter; Rohde, Bernhard; Selzer, Paul (2000). . „Fast Calculation of Molecular Polar Surface Area as a Sum of Fragment-Based Contributions and Its Application to the Prediction of Drug Transport Properties”. Journal of Medicinal Chemistry. 43 (20): 3714—3717. PMID 11020286. doi:10.1021/jm000942e.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]